Skip to main content

Cue Biopharma, Inc. (CUE) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $30.41 (+106.32%)

Consensus Target
$4.33
Upside
-85.8%
Analysts
Rating

Price Target Range

Low $2.00Consensus $4.33High $7.00
▲ Current $30.41

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

No rating trend data.

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Nov 15, 2024Maury RaycroftJefferies$4.00-86.8%
Jul 26, 2024Reni BenjaminJMP Securities$2.00-93.4%
Mar 13, 2024Maury RaycroftJefferies$6.00-80.3%
Nov 20, 2022Edward TenthoffPiper Sandler$7.00-77.0%

CUE vs Sector & Market

MetricCUEHealthcare AvgLarge Cap Avg
Analyst Rating2.242.41
Analyst Count818
Target Upside-85.8%+1150.4%+14.9%
P/E Ratio-1.696.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$1M$1M$1M1
2027-12-31$1M$1M$1M1
2028-12-31$1M$1M$1M1
2029-12-31$1M$1M$1M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.58$-0.58$-0.581
2027-12-31$-0.60$-0.60$-0.601
2028-12-31$-0.51$-0.51$-0.511
2029-12-31$-0.52$-0.52$-0.521

Frequently Asked Questions

What is the analyst consensus for CUE?

The consensus among 0 analysts covering Cue Biopharma, Inc. (CUE) is — with an average price target of $4.33.

What is the highest price target for CUE?

The highest price target for CUE is $7.00, set by Edward Tenthoff at Piper Sandler on 2022-11-20.

What is the lowest price target for CUE?

The lowest price target for CUE is $2.00, set by Reni Benjamin at JMP Securities on 2024-07-26.

How many analysts cover CUE?

0 analysts have issued ratings for Cue Biopharma, Inc. in the past 12 months.

Is CUE a buy or sell right now?

Based on 0 analyst ratings, CUE has a consensus rating of — with a -85.8% upside to the consensus target of $4.33.

What are the earnings estimates for CUE?

Analysts estimate CUE will report EPS of $-0.58 for the period ending 2026-12-31, with revenue estimated at $1M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.